The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

阿布勒 髓系白血病 蛋白激酶结构域 酪氨酸激酶 K562细胞 激酶 癌症研究 生物 药理学 化学 白血病 细胞生物学 生物化学 突变体 信号转导 免疫学 基因
作者
Paul W. Manley,Louise Barys,Sandra W. Cowan‐Jacob
出处
期刊:Leukemia Research [Elsevier BV]
卷期号:98: 106458-106458 被引量:129
标识
DOI:10.1016/j.leukres.2020.106458
摘要

Asciminib is a potent, orally bioavailable, investigational drug that specifically and potently inhibits the tyrosine kinase activity of native ABL1, together with that of the chimeric BCR-ABL1 oncoprotein which causes chronic myeloid leukemia (CML). In contrast to ATP-competitive BCR-ABL1 kinase inhibitors employed to treat CML that target multiple kinases, asciminib binds to the myristate binding pocket on the kinase domains of ABL1 and BCR-ABL1. Hitherto no drugs have been developed whose mechanism of action involves interacting with myristate binding pockets on proteins, and analysis of the structures of such binding sites in proteins other than ABL1/ABL2/BCR-ABL1 strongly suggest that asciminib will not bind to these with high affinity. Accordingly, the drug has no known safety liabilities resulting from any off-target activity, as illustrated by its specificity towards cells expressing BCR-ABL1 and lack of effects on non-kinase targets in biochemical screens. Because asciminib does not bind to the ATP-binding site it maintains substantial activity against kinase domain mutations that impart acquired drug resistance to ATP-competitive drugs. However, in vitro studies in cells have identified BCR-ABL1 mutations that reduce the anti-proliferative activity of asciminib, some of which are associated with clinical resistance towards the drug in patients. Here we review effects of asciminib on mutant forms of BCR-ABL1, analyse their sensitivity towards the drug from a structural perspective and affirm support for employing combinations with ATP-competitive inhibitors to impede the reactivation of BCR-ABL1 kinase activity in patients receiving monotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
GUESSSS发布了新的文献求助10
刚刚
1秒前
ainiyiwannian完成签到,获得积分10
1秒前
Mars完成签到,获得积分10
1秒前
2秒前
shan发布了新的文献求助10
3秒前
悦耳从波的应助被wang采纳,获得10
3秒前
小黑皮完成签到,获得积分10
4秒前
Beni完成签到,获得积分10
5秒前
边伯贤完成签到 ,获得积分10
5秒前
无花果的应助被谨慎的秋烟采纳,获得10
6秒前
眯眯眼的谷冬完成签到 ,获得积分10
6秒前
agog完成签到,获得积分10
6秒前
HYZJIA1完成签到 ,获得积分10
7秒前
砚行书完成签到,获得积分10
8秒前
醉熏的灵安完成签到 ,获得积分10
8秒前
8秒前
挚友发布了新的文献求助20
8秒前
Ava的应助被peace采纳,获得10
9秒前
慕容平安发布了新的文献求助10
10秒前
Sirius完成签到,获得积分10
11秒前
灰太狼完成签到,获得积分10
11秒前
珍波椰冰冰完成签到,获得积分10
11秒前
糊涂的飞珍完成签到,获得积分10
11秒前
张新宁完成签到,获得积分10
12秒前
饭团发布了新的文献求助10
12秒前
小白完成签到,获得积分0
13秒前
13秒前
糖糖发布了新的文献求助30
13秒前
专注笑南完成签到 ,获得积分10
15秒前
悦耳从波的应助被wh采纳,获得10
15秒前
小生不才完成签到,获得积分10
15秒前
GUESSSS发布了新的文献求助10
16秒前
自然的以亦完成签到,获得积分10
16秒前
过时的访天完成签到,获得积分10
18秒前
海绵宝宝发布了新的文献求助10
18秒前
19秒前
19秒前
ZYWu完成签到,获得积分10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211